bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Time to Sell?

bioMerieux (OTCMKTS:BMXMF) gapped down before the market opened on Monday . The stock had previously closed at $84.0750, but opened at $78.16. bioMerieux shares last traded at $78.16, with a volume of 65 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have commented on BMXMF shares. UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft lowered bioMerieux from a “buy” rating to a “hold” rating in a research note on Friday, April 24th. Piper Sandler started coverage on bioMerieux in a research report on Thursday. They issued a “neutral” rating for the company. Finally, Zacks Research upgraded bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold”.

bioMerieux Trading Up 1.1%

The stock has a 50-day moving average of $90.87 and a 200-day moving average of $109.35. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.